Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 0 | 0 | 886 | 2,329 | 18,739 |
| Gross Profit | N/A | N/A | 886 | 2,329 | 18,739 |
| Operating Expenses | 209,562 | 208,566 | 243,189 | 87,110 | 84,388 |
| Operating Income | -209,562 | -208,566 | -242,303 | -84,781 | -65,649 |
| Other Income | 54,344 | 599 | -96,513 | 830 | -11 |
| Pre-tax Income | -155,218 | -207,967 | -338,816 | -83,951 | -65,660 |
| Income Tax | -15 | 51 | -26 | -136 | 141 |
| Net Income Continuous | -155,203 | -208,018 | -338,790 | -83,815 | -65,801 |
| Net Income | $-155,203 | $-208,018 | $-338,790 | $-83,815 | $-65,801 |
| EPS Basic Total Ops | -2.42 | -4.42 | -49.12 | -24.86 | -25.02 |
| EPS Basic Continuous Ops | -2.42 | -4.42 | -49.12 | -24.86 | -25.02 |
| EPS Diluted Total Ops | -2.42 | -4.42 | -49.12 | -24.86 | -25.02 |
| EPS Diluted Continuous Ops | -2.42 | -4.42 | -49.12 | -24.86 | -25.02 |
| EPS Diluted Before Non-Recurring Items | -1.98 | -3.18 | -29.98 | -24.75 | -25.00 |
| EBITDA(a) | $-209,562 | $-208,566 | $-241,339 | $-83,144 | $-63,100 |